Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer

NCT03416153 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

OTHER

Sponsor class

Conditions

Oropharynx Cancer

Interventions

DRUG: Carboplatin
RADIATION: Radiation Therapy
DRUG: Paclitaxel

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]
[object Object]